Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from William Blair

Tesla Just Set a New Quarterly Delivery Record. Should You Buy TSLA Stock Here?

Tesla’s quarterly deliveries climb to a record 497,100 units in the third quarter. William Blair says it’s getting hard to stick with its neutral stance on TSLA stock.

Barchart

Could This New Drug Be The Safer Way To Fight Obesity?

On Friday, Skye Bioscience, Inc. (NASDAQ:SKYE) announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting.

Benzinga

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Telix Gets Second FDA Rejection For Kidney Cancer Drug

On Thursday, Telix Pharmaceuticals Limited (NASDAQ:TLX) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix, 89Zr-DFO girentuximab), an investigational PET2 agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC).

Benzinga

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

William Blair initiated coverage on Insmed Incorporated (NASDAQ:INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

Benzinga

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction

In a stunning reversal, Dr. Vinay Prasad is returning to his role as director of the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), just days after his resignation.

Benzinga

Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst

Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Elanco Animal Health Soars Past 52-Week High On Strong Sales, Raised Annual Outlook

Elanco Animal Health Incorporated (NYSE:ELAN) reported second-quarter 2025 results on Thursday, posting adjusted earnings per share of 26 cents, down 13% year over year.

Benzinga

Weakness In Vertex Stock Seen As Buying Opportunity

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stock is falling on Tuesday after the company’s pain data overshadowed strong second-quarter earnings.

Benzinga

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) reported second-quarter adjusted earnings of $1.44, up 50% year over year, beating the consensus of 85 cents and sales of $825.41 million, up 16%, beating the consensus of $760.39 million.

Benzinga

Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline

Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61.

Benzinga

Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics

The U.S. Food and Drug Administration approved on Monday PTC Therapeutics, Inc.’s (NASDAQ:PTCT) SEPHIENCE (sepiapterin) for children and adult patients with phenylketonuria (PKU).

Benzinga

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans

Exelixis Inc. (NASDAQ:EXEL) on Monday reported its first quarter of 2025 adjusted earnings of 75 cents per share, compared to 85 cents a year ago, beating the consensus of 56 cents.

Benzinga

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

The U.S. Food and Drug Administration approved on Monday Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Incyte Corporation (NASDAQ:INCY) reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion.

Barchart

Tesla Just Signed a Chip Supply Deal with Samsung. What Does That Mean for TSLA Stock?

Tesla stock inches up as the EV maker announces a $16.5 billion deal with Samsung Electronics. William Blair still remains dovish on TSLA shares for the second half of 2025.

Benzinga

ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery

Clinical research organization ICON plc (NASDAQ:ICLR) stock is surging on Thursday after the company reported better-than-expected second-quarter financial results and raised its fiscal 2025 sales guidance.

Benzinga

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets

On Friday, the U.S. Food and Drug Administration placed Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) investigational gene therapy clinical trials for limb girdle muscular dystrophy (LGMD) on a clinical hold.

Benzinga

Sarepta Therapeutics' Reorganization Boosts Investor Confidence

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after the company issued an after-hours update on ongoing label expansion efforts for Elevidys, its approved gene therapy for Duchenne muscular dystrophy.

Barchart

Is Palantir Stock a Buy, Sell, or Hold on New Nuclear Deal?

Palantir stock remains in focus as the big data analytics firm teamed up with The Nuclear Company. William Blair recommends caution in buying PLTR shares.

Barchart

QuantumScape Just Announced a Major Cobra Milestone. How Should You Play QS Stock Here?

QuantumScape stock soars on successful integration of Cobra separator process into baseline cell production. William Blair recommends selling QS shares before they fade again.

Barchart

Palantir Is Reportedly Building a US ‘Spy Machine.’ How Should You Play PLTR Stock Here?

Palantir is reportedly building a “spy machine” for the Trump administration. William Blair remains bearish on PLTR shares for the remainder of 2025.

Fortune

Legal tech startup ProfitSolv seeks buyer amid sluggish merger climate

Bankers don’t expect “Trump Bump” will boost mergers this year

Barchart

Palantir Stock Gets Upgrade: Is it Time to Buy PLTR After Recent Slump?

Leading broker William Blair, an erstwhile cynic has recently upgraded the stock.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.